United Kingdom-based GlaxoSmithKline (GSK) plc has offered its technology license for its clinical-stage Ebola vaccines to the Sabin Vaccine Institute, a United States-based non-profit organisation that promotes global vaccine development, it was reported yesterday.
The contracts between both firms have been signed for progressing the development of the prophylactic candidate Ebola vaccines against the Ebola Zaire, Ebola Sudan and the Marburg virus. According to the contracts, Sabin has also acquired certain patent rights regarding the Ebola vaccines. The three candidate vaccines were developed initially through a partnership between the US National Institutes of Health and Okairos that was acquired by GSK in 2013. GSK says that the three ChAd3-based vaccines have so far shown a strong safety profile and promising immunogenicity results after being administered to over 5,000 adults and 600 children, in 13 different clinical trials.
GSK Vaccines chief medical officer, Thomas Breuer, said, 'These agreements with the Sabin Vaccine Institute are an important next step in the fight against Ebola and Marburg viruses. Enabling Sabin to build on the scientific progress GSK has delivered up to Phase II increases the likelihood these candidate vaccines may help prevent potential future outbreaks, and exemplifies GSK's approach to global health vaccines which supports partners in taking forward our innovations in a sustainable way.'
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine